These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25555662)

  • 1. Complications and continuation rates associated with 2 types of long-acting contraception.
    Berenson AB; Tan A; Hirth JM
    Am J Obstet Gynecol; 2015 Jun; 212(6):761.e1-8. PubMed ID: 25555662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L; Brache V; Meirik O; Ali M; Habib N; Landoulsi S;
    Hum Reprod; 2015 Nov; 30(11):2527-38. PubMed ID: 26409014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study.
    Short M; Dallay D; Omokanye S; Hanisch JU; Inki P
    Eur J Contracept Reprod Health Care; 2012 Feb; 17(1):79-88. PubMed ID: 22200172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of long-acting, progestin-only contraception in Europe: a two-year prospective, non-interventional study.
    Short M; Dallay D; Omokanye S; Stauch K; Inki P
    Eur J Contracept Reprod Health Care; 2014 Feb; 19(1):29-38. PubMed ID: 24289528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z; Madden T; Zhao Q; Secura GM; Allsworth JE; Peipert JF
    Contraception; 2013 Oct; 88(4):503-8. PubMed ID: 23582238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant.
    Ali M; Akin A; Bahamondes L; Brache V; Habib N; Landoulsi S; Hubacher D;
    Hum Reprod; 2016 Nov; 31(11):2491-2498. PubMed ID: 27671673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
    Bahamondes L; Brache V; Ali M; Habib N;
    Contraception; 2018 Sep; 98(3):181-187. PubMed ID: 29777663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two year continuation rates of contraceptive methods in France: a cohort study from the French national health insurance database.
    Agostini A; Godard C; Laurendeau C; Benmahmoud Zoubir A; Lafuma A; Lévy-Bachelot L; Gourmelen J; Linet T
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):421-426. PubMed ID: 30499732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
    McNicholas C; Swor E; Wan L; Peipert JF
    Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The levonorgestrel intrauterine system: cohort study to assess satisfaction in a postpartum population in Kenya.
    Hubacher D; Masaba R; Manduku CK; Chen M; Veena V
    Contraception; 2015 Apr; 91(4):295-300. PubMed ID: 25601351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review.
    Sanders JN; Turok DK; Gawron LM; Law A; Wen L; Lynen R
    Am J Obstet Gynecol; 2017 Jun; 216(6):590.e1-590.e8. PubMed ID: 28188772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate postabortion initiation of levonorgestrel implants reduces the incidence of births and abortions at 2 years and beyond.
    Rose SB; Garrett SM; Stanley J
    Contraception; 2015 Jul; 92(1):17-25. PubMed ID: 25818594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Female sexual function in women using LARC methods.
    Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
    Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis.
    Law A; Liao L; Lin J; Yaldo A; Lynen R
    Contraception; 2018 Apr; ():. PubMed ID: 29684326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making.
    Hubacher D; Masaba R; Manduku CK; Veena V
    Contraception; 2013 Jul; 88(1):97-102. PubMed ID: 23566383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
    Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
    Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.